Longevity & Cellular Research Peptides: Epithalon, NAD+, SS-31, FOXO4 & MOTS-c

Short answer: Longevity-focused research peptides such as GHK-Cu and growth-axis compounds are studied for cellular, mitochondrial, and senescence-related research. They are investigational research tools, not anti-aging treatments.

“Longevity peptides” is a phrase that promises far more than the underlying science can currently deliver. The compounds grouped under this heading — epithalon, NAD+, SS-31 (elamipretide), FOXO4-DRI, and MOTS-c — are interesting precisely because they probe distinct, well-defined cellular aging mechanisms: telomere maintenance, mitochondrial energetics, and cellular senescence. But “interesting mechanism in a model system” is not the same as “validated anti-aging intervention in humans.” This overview walks through what each compound is genuinely thought to do, the experimental contexts in which those findings were generated, and the very real limits of that evidence. Everything described here is preliminary, and every compound discussed is for research use only — not for human consumption.

The Three Mechanistic Themes Behind ‘Cellular Aging’ Research

Aging biology is not a single process, and no single peptide addresses it. Most longevity-adjacent research compounds cluster around three distinct hallmarks of aging that have been characterized in cell and animal models. Understanding which theme a compound touches is the most honest way to read claims about it.

Telomere maintenance — Telomeres are the repetitive DNA caps at chromosome ends that shorten with each cell division. Telomerase, the enzyme that can extend them, is the focus of epithalon research.
Mitochondrial integrity & bioenergetics — Mitochondria generate cellular ATP and accumulate damage over time. NAD+, SS-31, and MOTS-c all intersect with mitochondrial function, though by very different routes.
Cellular senescence — Senescent cells stop dividing but resist death and secrete inflammatory signals (the SASP). FOXO4-DRI research targets the survival machinery of these cells.

Why the framing matters

A compound that influences telomerase activity in cultured cells has demonstrated a molecular effect — not a lifespan benefit. Mechanistic plausibility is the starting point of research, not its conclusion. Keep that distinction in mind throughout this article.

For a broader, cross-class look at how peptides interact with cellular receptors and signaling pathways, see our peptide mechanisms of action pillar. The compounds below sit within our specialty compounds category.

Epithalon and Telomere Research

Epithalon (also written epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from epithalamin, a pineal gland extract studied extensively in Russian gerontology research beginning in the late 20th century. It is the compound most directly associated with the telomere theme.

The proposed mechanism

In cell-culture studies, epithalon has been reported to influence telomerase activity — the enzyme that adds telomeric repeats to chromosome ends. Some in-vitro work using human somatic cell lines reported increased telomerase expression and telomere elongation following exposure to the peptide. The hypothesized broader role is as a peptide bioregulator acting on gene expression, consistent with the bioregulator framework advanced by Vladimir Khavinson and colleagues.

The honest limits

Much of the foundational epithalon literature originates from a single research lineage, was published decades ago, and has seen limited independent replication outside that group. Telomerase activation is also mechanistically double-edged: telomerase is upregulated in most cancers, so any compound proposed to increase it warrants particular caution and is exactly the kind of claim that requires rigorous, independent confirmation before any conclusion. In research settings, epithalon is studied as a tool to probe telomere and pineal-axis biology — not as a validated intervention.

Researchers working with this peptide can review epithalon product details for specification and certificate-of-analysis information.

NAD+ and Cellular Energy Metabolism

NAD+ (nicotinamide adenine dinucleotide) is not a peptide — it is a coenzyme central to cellular metabolism — but it appears throughout longevity research and is included here because it anchors much of the field’s interest in metabolic aging.

NAD+ is required for redox reactions that drive ATP production, and it is consumed as a substrate by several important enzyme families, most notably the sirtuins (NAD+-dependent deacetylases implicated in stress response and metabolic regulation) and PARPs (involved in DNA repair). A well-established observation across multiple species is that tissue NAD+ levels tend to decline with age, which has motivated extensive research into whether restoring NAD+ availability can influence age-related cellular dysfunction.

Mechanism vs. outcome

That NAD+ declines with age and that NAD+ supports sirtuin and PARP activity are well-supported facts. Whether raising NAD+ meaningfully slows aging processes in humans remains an active, unresolved research question. The basic biochemistry is solid; the longevity application is preliminary.

Most NAD+ research focuses on the coenzyme itself or its precursors and on the mitochondrial and nuclear pathways it feeds. Researchers can review NAD+ product details for specifications. Because NAD+ sits at the metabolic crossroads, it is frequently studied alongside the mitochondrial-targeted compounds discussed next.

SS-31 (Elamipretide) and Mitochondrial Integrity

SS-31, also known as elamipretide or MTP-131, is a synthetic tetrapeptide from the Szeto-Schiller family of mitochondria-targeting peptides. Unlike NAD+, which fuels metabolic enzymes broadly, SS-31 is notable for a specific structural property: it concentrates at the inner mitochondrial membrane.

The proposed mechanism

SS-31 is reported to associate selectively with cardiolipin, a phospholipid unique to the inner mitochondrial membrane that is essential for organizing the electron transport chain and stabilizing cristae structure. By binding cardiolipin, SS-31 is hypothesized to help preserve membrane organization and electron-transport efficiency, and to reduce the leakage of reactive oxygen species that occurs when these complexes become disorganized. This places SS-31 squarely in the mitochondrial-integrity theme of aging research.

Where the evidence stands

Elamipretide has been the subject of clinical-research investigation in conditions characterized by mitochondrial dysfunction — an unusual level of formal study for a compound in this space. That said, results across those research programs have been mixed and outcomes are condition-specific, so the picture is far from settled. The cardiolipin-binding mechanism is among the better-characterized in this group, but a defined mechanism does not by itself establish efficacy for any aging-related endpoint.

Specification information is available on the SS-31 product page. A structurally and conceptually adjacent mitochondrial peptide is discussed below.

MOTS-c: A Mitochondrial-Derived Peptide

MOTS-c approaches mitochondrial biology from a different and conceptually striking angle. It is a mitochondrial-derived peptide — a short peptide encoded within the mitochondrial genome itself (within the 12S rRNA region) rather than by nuclear DNA. This makes it part of a small, relatively recently characterized class of signaling molecules that originate inside the mitochondrion.

The proposed mechanism

Research has characterized MOTS-c primarily as a regulator of metabolic homeostasis. In cell and animal models it has been associated with activation of the AMPK pathway — a central cellular energy sensor — and with influences on glucose handling and metabolic stress responses. Some studies report that under metabolic or oxidative stress, MOTS-c can translocate to the nucleus and modulate stress-adaptive gene expression, positioning it as a signal that coordinates mitochondrial and nuclear responses.

An emerging class

Mitochondrial-derived peptides are a young area of biology. MOTS-c is among the best studied of them, but ‘best studied’ here still means primarily preclinical and mechanistic. Treat it as a research probe into mitochondrial-nuclear signaling rather than an established intervention.

Researchers can review the MOTS-c product page for details. Because MOTS-c, NAD+, and SS-31 all touch mitochondrial and metabolic energetics from different directions, they are often considered together when mapping this corner of the field.

FOXO4-DRI and the Senescence Theme

FOXO4, in its research form usually a D-retro-inverso peptide (FOXO4-DRI), targets the third aging theme: cellular senescence. Senescent cells have permanently exited the cell cycle but resist apoptosis and persist in tissues, where their secreted inflammatory factors (the senescence-associated secretory phenotype, or SASP) are thought to contribute to age-related tissue dysfunction.

The proposed mechanism

The FOXO4-DRI hypothesis centers on the interaction between the transcription factor FOXO4 and the tumor-suppressor protein p53. In senescent cells, FOXO4 is proposed to help sequester p53 in the nucleus, keeping these cells alive despite their damage. FOXO4-DRI is designed to interfere with the FOXO4–p53 interaction, the idea being to release p53 and selectively push senescent cells toward apoptosis — a ‘senolytic’ concept. This mechanism was reported in influential mouse-model studies.

The honest limits

The senolytic concept is genuinely exciting at a research level, but FOXO4-DRI evidence remains largely preclinical, and selectively removing senescent cells without disrupting normal cells is a substantial and unresolved challenge. The compound is best understood as a tool for studying senescence and the FOXO4–p53 axis in model systems. Specification details are on the FOXO4 product page.

Comparing the Compounds at a Glance

The table below summarizes the aging theme, proposed mechanism, and evidence maturity for each compound. ‘Evidence maturity’ is a deliberately conservative reading of how far the research has progressed — not an endorsement.

Compound	Type	Aging theme	Proposed mechanism (per research)	Evidence maturity
Epithalon	Synthetic tetrapeptide	Telomere maintenance	Influence on telomerase activity / gene expression	Mostly older, single-lineage; limited independent replication
NAD+	Coenzyme (not a peptide)	Mitochondrial / metabolic energetics	Substrate for sirtuins & PARPs; declines with age	Strong basic biochemistry; longevity application unresolved
SS-31 (elamipretide)	Synthetic tetrapeptide	Mitochondrial integrity	Cardiolipin binding; stabilizes inner membrane / ETC	Most clinical-research exposure of the group; mixed results
MOTS-c	Mitochondrial-derived peptide	Mitochondrial / metabolic signaling	AMPK activation; metabolic-stress gene regulation	Emerging class; primarily preclinical
FOXO4-DRI	D-retro-inverso peptide	Cellular senescence	Disrupts FOXO4–p53; senolytic concept	Largely preclinical (mouse models)

Research use only

None of the compounds in this article are approved as anti-aging treatments, and nothing here should be read as a protocol, dosing guidance, or therapeutic recommendation. All are offered strictly for laboratory research. See our research disclaimer for full terms.

For storage and handling of lyophilized material, researchers should review peptide reconstitution and storage, and consult the full research disclaimer before any laboratory work.

Common questions

Are these ‘longevity peptides’ proven to extend lifespan?

No. Each compound has a defined mechanism studied in cell or animal models, and in the case of SS-31 some clinical research, but none has been established as a lifespan-extending intervention in humans. The strength of this field is mechanistic plausibility, not validated outcomes. They are research tools for studying aging biology, supplied for research use only.

What is the difference between SS-31 and MOTS-c, since both relate to mitochondria?

They engage mitochondria in fundamentally different ways. SS-31 is a synthetic peptide that physically associates with cardiolipin at the inner mitochondrial membrane to help preserve membrane and electron-transport organization. MOTS-c is a peptide encoded by the mitochondrial genome itself that acts as a metabolic signal, associated with AMPK pathway activation and stress-responsive gene expression.

Why is telomerase activation considered a cautious area of research?

Telomerase extends telomeres, but it is also upregulated in the majority of cancers, where it supports unlimited cell division. Any compound proposed to increase telomerase activity — as epithalon has been in some in-vitro reports — therefore carries an inherent double-edged consideration that makes rigorous, independent confirmation especially important before drawing conclusions.

Is NAD+ a peptide?

No. NAD+ is a coenzyme (nicotinamide adenine dinucleotide), not a peptide. It is included in longevity discussions because it is central to mitochondrial energy metabolism and serves as the substrate consumed by sirtuins and PARPs, and because tissue NAD+ levels are well documented to decline with age across multiple species.

What does ‘senolytic’ mean in the context of FOXO4-DRI research?

A senolytic is a compound studied for its ability to selectively eliminate senescent cells — cells that have stopped dividing but resist death and secrete inflammatory factors. FOXO4-DRI is researched as a senolytic concept because it is designed to disrupt the FOXO4–p53 interaction that helps senescent cells survive. This work is largely preclinical and selectivity remains a major challenge.

References

Khavinson VK, et al. Peptide promotes overcoming of the division limit in human somatic cell. Bulletin of Experimental Biology and Medicine — research on epithalon and telomerase activity.
Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology, 2014.
Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 2015.
Baar MP, et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging (FOXO4-DRI). Cell, 2017.

Banger Labs supplies materials for laboratory and research use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease. Statements have not been evaluated by the FDA.